Multiple organ dysfunction as a complication of Bacille Calmette-Guérin intravesical instillation (BCG)
report of a case an literature review
Abstract
Bacille Calmette-Guérin intravesical instillation (BCG) is the main treatment for superficial transitional cell carcinoma of the bladder. In spite of it being a safe procedure, severe complications as granulomatous hepatitis, osteomyelitis, pneumonia, sepsis and multiple organ dysfunction syndrome occur in a few patients. The study presents the case of a patient with a diagnosis of superficial transitional cell carcinoma of the bladder (T1), who died as a consequence of a severe systemic compromise of the central nervous system, secondary to instravesical instillation of BCG.
References
(1) Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer- indications and limitations. BJU Int 2012; 110(suppl 4):12-21.
(2) Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174(1):86-91
(3) Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016; 196(4):1021-9.
(4) Fine PEM, Carneiro IAM, Milstein JB, Clements CJ. Issues relating to the use of BCG in immunization programs. Geneva: WHO; 1999.
(5) Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116(2):180-3.
(6) Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesicalbacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis 2000; 31(Suppl 3):S91-3.
(7) Lamm DL. Efficacy and safety of bacilleCalmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31(Suppl 3): S86-90.
(8) Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147(3):596-600.
(9) Vazquez-Lavista LG, Flores-Balcazar CH, Llorente L. El bacilo Calmette-Guérin como inmunomodulador en el cáncer de vejiga. Rev Invest Clin 2007; 59(2):146-52.
(10) Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, et al. Intravesical chemotherapy plus bacilleCalmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int 2013; 111(6):977-83.
(11) Jokisch JF, Karl A, Stief C. Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian J Urol 2015; 31(4):304-11.
(12) Dabrowska M, Drabarek T, Muraszko-Klaudel A, Slawek J. A thoracic tuberculous spondylodisctis after intravesical BCG immunotherapy of bladder cancer: case report and literature review. NeurolNeurochir Pol 2015; 49(6):460-6.
(13) Frattini G, Fernández Monteverde H, Nigro M, D'Auria M, Lorenzo H, Castorina A. Complicaciones de la inmunoterapia endovesical con BCG. Rev Argent Urol 1997; 62(4):137-44.
(14) Nadasy KA, Patel RS, Emmett M, Murillo RA, Tribble MA, Black RD, et al. Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma. South Med J 2008; 101(1):91-5.
(15) Nemeth J, Stoiser B, Winkler HM, Müllauer L, Graninger W, Winkler S. Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy. Wien KlinWochenschr 2008; 120(3-4):1213.
(16) Ozbakkaloglu B, Tünger O, Sürücüoglu S, Lekili M, Kandiloglu AR. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy. IntUrolNephrol 1999; 31(1):49-53.
(17) Viallard JF, Denis D, Texier-Maugein J, Parrens M, Faure I, Pellegrin JL, et al. Disseminated infection after bacilleCalmette-Guérin instillation for treatment of bladder carcinoma. Clin Infect Dis 1999; 29(2):451-2.
(18) González OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al. Spectrum of bacilleCalmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36(2):140-8.
(19) Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido A, San Juan R, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014; 93(17):236-54.
(20) Colomba C, Di Carlo P, Guadagnino G, Siracusa L,Trizzino M, Gioè C, et al. A case of epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection. Infect Agent Cancer 2016; 11:25.
(21) Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014; 65(1):69-76.
(22) Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. EurUrol 2013; 63(3):462-72.
(23) Brosman SA. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. J Urol 1985; 134(1):36-9.
(24) Macleod LC, Ngo TC, Gonzalgo ML. Complications of intravesical bacillus Calmette-Guerin. Can UrolAssoc J 2014; 8(7-8):E540-4.
(25) Márquez-Batalla S, Fraile-Villarejo E, Belhassen-García M, Gutiérrez-Zubiaurre N, Cordero-Sánchez M. Disseminated infection due to Mycobacterium bovis after intravesical BCG instillation. World J Clin Cases 2014; 2(7):301-3.
(26) Fournier A, Gouriet F, Fournier PE, Casalta JP, Saby L, Habib G, et al. A case of infectious endocarditis due to BCG. Int J Infect Dis 2015; 35:27-8.
(27) Harbjerg JL, Bjerre CC, Lillebæk T, Weinreich UM. Pulmonal bacillus Calmette-Guérin infection two years after intravesical bacillus Calmette-Guérin installation. UgeskrLaeger 2014; 176(25A). pii: V07120381. Article in Danish.
(28) Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol 2014; 11(3):153-62.
(29) Grange JM. Complications of bacilli Calmette-Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998; 1(2):84-8.
(30) Debois H, Loupi E, Saliou P. Surveillance of the safety of intravesical BCG therapy in France: quantitative analysis of serious adverse events notified over a period of five years. Prog Urol 2002; 12(4):604-8. Article in French.
(31) Decaestecker K, Oosterlinck W. Managing the adverse events of intravesical bacillus Calmette-Guérin therapy. Res Rep Urol 2015; 7:157-63.
(32) Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al; EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57(5):766-73.
(33) Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, et al; Club Urológico Español de Tratamiento Oncológico. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89(7):671-80.
(34) Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG; Club Urológico Español de Tratamiento Oncológico. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospectiverandomized trial. J Urol 2005; 174(4 Pt 1):1242-7.
(35) Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, et al; Club Urológico Español De Tratamiento Oncológico. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. EurUrol 2007; 52(5):1398-406.
(36) Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, et al; European Organization for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 2001; 165(2):401-3.
(37) Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176(3):935-9.
(38) Watts MR, Taylor PC, Sintchenko V, Whelan CM, Farnsworth RH, Jones P, et al. Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. Clin Infect Dis 2011; 52(1):86-93.
(39) González-Del Vecchio M, Ruíz-Serrano MJ, Gijón P, Sánchez-Somolinos M, de Egea V, et al. Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital. DiagnMicrobiol Infect Dis 2016; 85(3):338-43.
(40) Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19(3):565-72.
(41) Golub V, Malhotra P, Patel S. Mycobacterial brain tuberculomas due to BacilleCalmette-Guérinintravesical chemotherapy for bladder cancer: a case report and literature review. Can J infect Dis Med Microbiol 2011; 22(3):104-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
